Identify and Evaluate Manufacturer-Level Drug Utilization and Switching Patterns in Sentinel

Project Title Identify and Evaluate Manufacturer-Level Drug Utilization and Switching Patterns in Sentinel
Date Posted
Monday, December 12, 2016
Status
In progress
Deliverables
Description

The Office of Generic Drugs (OGD) at the Center for Drug Evaluation and Research (CDER) is interested in exploring the potential for the Sentinel System to support investigations of manufacturer-level product switching. The aims of this project are: 

  1. Design, develop, test and evaluate a flexible and reusable prototype analytic tool that could be used to conduct rapid population-based assessments on new generic products in the future; and
  2. Use the Sentinel System to characterize utilization and switching patterns associated with two use-cases: Toprol XL (metoprolol ER) and Lamictal XR (lamotrigine ER). 
Workgroup Leader(s)

Jennifer Popovic, DVM, MA, Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, MA; Sarah Dutcher, PhD, Office of Research and Standards/Office of Generic Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD; Joshua Gagne, PharmD, ScD, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Boston; Michael Nguyen, MD, Sukhminder Sandhu, PhD, MPH, MS, Joel Weissfeld, MD, MPH, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD

 

Workgroup Members

Rima Izem, PhD, Yueqin Zhao, PhD, Office of Biostatistics, Center for Drug Evaluation and Research, FDA, Silver Spring, MD; Wenlei Jiang, PhD, Zhong (John) Wang, PhD, Office of Research and Standards/Office of Generic Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD; Patty Greene, PharmD, Aaron Niman, Simone Pinheiro ScD, MSc, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD; Timothy Glavin, Adee Kennedy, MS, MPH, Andrew Petrone, MPH, Darren Toh, ScD, Anita Wagner, PharmD, MPH, DrPH, Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, MA;

Medical Product
Toprol XL
metoprolol ER
Lamictal XR
lamotrigine ER
Time Period
May 2016- June 2017
Data Sources
Sentinel Distributed Database